T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for most subtypes of T cell lymphoma because T cell lymphomas are relatively rare, representing about 15% of all non-Hodgkin's lymphomas diagnosed annually. Many T cell lymphoma subtypes, perhaps a majority, have a relatively poor prognosis with or without T cell lymphoma treatment.
First-Line T Cell Lymphoma Treatment
First-line therapeutic intervention for cases of noncutaneous peripheral T cell lymphomas remains relatively poorly explored, but some chemotherapy regimens are advocated in widely published T cell lymphoma treatment guidelines, such as:
- -- CHOP (cyclophosphamide, vincristine, doxorubucin and prednisone)
- -- DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin)
- -- HyperCVAD (doxorubicin, vincristine, cyclophosphamide and dexamethasone)
- -- High dose chemotherapy followed by a stem cell transplantation
Some T cell lymphoma patients may be guided towards a clinical trial as first-line therapy, depending on the diagnosis, staging, and other factors.
Second-Line T Cell Lymphoma Treatment
Second-line therapies for T cell lymphoma treatment include the following combination chemotherapy regimens, provided the patient is a candidate for stem cell transplantation:
- -- DHAP (dexamethasone, cisplatin and cytarabine)
- -- ESHAP (etopiside, methylprednisolone, cytarabine and cisplatin)
- -- GDP (gemcitabine, dexamethasone and cisplatin
- -- ICE (ifosfamide, carboplatin, etoposide)
- -- MINE (mesna, ifosfamide, mitoxantrone and etoposide
- -- Pralatrexate
- -- GemOx (gemcitabine and oxaliplatin)
Similar to first-line options, for some patients referral to a clinical trial may constitute second-line therapy.
If the patient is not a candidate for stem cell transplantation, possible second-line therapies include the following:
- -- Alemtuzumab
- -- Bortezomib
- -- Denileukin diftitox
- -- Gemcitabine
- -- Pralatrexate
- -- Radiation
T cell lymphoma treatment options for less common T cell lymphoma subtypes, such as Adult T cell Leukemia/Lymphoma, as well as for cutaneous T cell lymphomas, will differ from what is presented here.
Source
National Comprehensive Cancer Network, Practice Guidelines in Oncology v.1.2010, Peripheral T-Cell Lymphomas
